0001144204-16-116981.txt : 20160805 0001144204-16-116981.hdr.sgml : 20160805 20160805193034 ACCESSION NUMBER: 0001144204-16-116981 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160803 FILED AS OF DATE: 20160805 DATE AS OF CHANGE: 20160805 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spark Therapeutics, Inc. CENTRAL INDEX KEY: 0001609351 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462654405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 888-772-7560 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mehra Anand CENTRAL INDEX KEY: 0001590102 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36819 FILM NUMBER: 161812316 MAIL ADDRESS: STREET 1: 3000 SAND HILL ROAD, 4-250 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 v446222_4.xml OWNERSHIP DOCUMENT X0306 4 2016-08-03 0 0001609351 Spark Therapeutics, Inc. ONCE 0001590102 Mehra Anand SOFINNOVA VENTURES 3000 SAND HILL ROAD, 4-250 MENLO PARK CA 94025 1 0 0 0 Common Stock 2016-08-03 4 S 0 4612 60 D 1407689 I See footnote Common Stock 2016-08-04 4 S 0 452 60 D 1407237 I See footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Venture Partners VIII, L.P. ("SVP VIII") on October 8, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.02, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The securities are owned directly by SVP VIII. Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein. /s/ Nathalie Auber, attorney-in-fact for Anand Mehra 2016-08-05